Stockscreener 앱 받기
8.92
7.08%
0.59
시장 영업 전:
8.87
-0.05
-0.56%
전일 마감가:
$8.33
열려 있는:
$8.27
하루 거래량:
77,263
Relative Volume:
0.40
시가총액:
$355.29M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+31.56%
1개월 성능:
+5.81%
6개월 성능:
-58.43%
1년 성능:
+0.00%
1일 변동 폭
$8.16
$9.01
1주일 범위
$6.84
$9.14
52주 변동 폭
$5.83
$26.25
Zenas Biopharma Inc Stock (ZBIO) Company Profile
명칭
Zenas Biopharma Inc
전화
857-271-2954
주소
852 WINTER STREET, SUITE 250, WALTHAM
ZBIO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ZBIO
Zenas Biopharma Inc
|
8.92 | 355.29M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Zenas Biopharma Inc Stock (ZBIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-20 | 개시 | Wedbush | Outperform |
| 2025-02-04 | 개시 | Wolfe Research | Outperform |
| 2024-12-16 | 개시 | H.C. Wainwright | Buy |
| 2024-11-05 | 개시 | Rodman & Renshaw | Buy |
| 2024-10-08 | 개시 | Citigroup | Buy |
| 2024-10-08 | 개시 | Guggenheim | Buy |
| 2024-10-08 | 개시 | Jefferies | Buy |
| 2024-10-08 | 개시 | Morgan Stanley | Overweight |
모두보기
Zenas Biopharma Inc 주식(ZBIO)의 최신 뉴스
ZBIO INVESTOR NOTICE: Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – Company AnnouncementFT.com - Financial Times
Shareholders of Zenas BioPharma, Inc. Should Contact The Gross Law Firm Before June 16, 2025 to Discuss Your RightsZBIO - marketscreener.com
Contrasting Zenas Biopharma (ZBIO) & Its Competitors - Defense World
ZBIO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - PR Newswire
Press Release Distribution & PR Platform - ACCESS Newswire
ZBIO Investors Have Opportunity to Lead Zenas BioPharma, Inc. Lawsuit Filed by The Rosen Law Firm - The Bradford Era
ROSEN, THE FIRST FILING FIRM, Encourages Zenas BioPharma, - GlobeNewswire
ROSEN, THE FIRST FILING FIRM, Encourages Zenas BioPharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – ZBIO - TradingView
ROSEN, THE FIRST FILING FIRM, Encourages Zenas BioPharma, Inc. Investors to Secure Counsel - Bluefield Daily Telegraph
ROSEN, THE FIRST FILING FIRM, Encourages Zenas BioPharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – ZBIO - GlobeNewswire Inc.
Shareholder Alert: Robbins LLP Informs Stockholders of the Zenas BioPharma, Inc. Class Action Lawsuit - PR Newswire
ZBIO INVESTOR ALERT: Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – Company AnnouncementFT.com - Financial Times
INVESTOR ALERT: Cohen Milstein Calls on Zenas BioPharma - GlobeNewswire
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Zenas BioPharma Faces Investor Suit Over Post-IPO Plunge - Law360
ZBIO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma - Business Wire
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of - GlobeNewswire
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Zenas BioPharma, Inc. (ZBIO) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm - TradingView
ZBIO INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Business Wire
Reviewing Zenas Biopharma (ZBIO) and Its Peers - Defense World
ZBIO INVESTOR NEWS: ROSEN, THE FIRST FILING FIRM, - GlobeNewswire
ZBIO Investors Have Opportunity to Lead Zenas BioPharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Business Wire
ZBIO INVESTOR NEWS: ROSEN, THE FIRST FILING FIRM, Encourages Zenas BioPharma, Inc. Investors to - Bluefield Daily Telegraph
ZBIO INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP - GlobeNewswire
ZBIO INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead the Zenas BioPharma Class Action Lawsuit - TradingView
ZBIO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - markets.businessinsider.com
EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Zenas BioPharma, Inc. – ZBIO - Business Wire
ZBIO Investor News: Rosen Law Firm Encourages Zenas BioPharma, Inc. Investors to Inquire About Securities Class Action InvestigationZBIO - PR Newswire
Zenas BioPharma, Inc. Announcement: If You Have Suffered - GlobeNewswire
Zenas BioPharma, Inc. Announcement: If You Have Suffered Losses in Zenas BioPharma, Inc. - Bluefield Daily Telegraph
Zenas BioPharma, Inc. Announcement: If You Have Suffered Losses in Zenas BioPharma, Inc. (NASDAQ: ZBIO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights - TradingView
Contrasting Zenas Biopharma (ZBIO) & The Competition - Defense World
Zenas BioPharma, Inc. Investor News: If You Have Suffered - GlobeNewswire
Zenas BioPharma, Inc. Investor News: If You Have Suffered Losses in Zenas BioPharma, Inc. - Bluefield Daily Telegraph
The Escalator: Rocket Pharmaceuticals, Zenas BioPharma, Angelini Ventures - Medical Marketing and Media
Critical Comparison: Zenas Biopharma (ZBIO) vs. Its Peers - Defense World
Zenas Biopharma (ZBIO) versus The Competition Head-To-Head Review - Defense World
Zenas Biopharma (ZBIO) and Its Competitors Financial Analysis - Defense World
Zenas BioPharma names Haley Laken as chief scientific officer - MSN
Zenas BioPharma names new Chief Scientific Officer By Investing.com - Investing.com South Africa
Zenas BioPharma names new Chief Scientific Officer - Investing.com Australia
Zenas: Differentiated B-Cell Targeting Drug With Q3 Of 2025 Catalyst (NASDAQ:ZBIO) - Seeking Alpha
Zenas BioPharma Appoints Haley Laken, Ph.D., as Chief Scientific Officer - The Manila Times
Zenas Biopharma (ZBIO) and Its Competitors Financial Review - Defense World
Zenas Biopharma Inc (ZBIO) 재무 분석
Zenas Biopharma Inc (ZBIO)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
Zenas Biopharma Inc 주식 (ZBIO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Xiao Ting | Director |
Feb 07 '25 |
Buy |
7.76 |
10,000 |
77,600 |
47,000 |
| MOULDER LEON O JR | Chief Executive Officer |
Dec 04 '24 |
Buy |
9.98 |
45,000 |
449,100 |
241,155 |
| MOULDER LEON O JR | Chief Executive Officer |
Dec 03 '24 |
Buy |
10.76 |
25,000 |
269,000 |
196,155 |
| MOULDER LEON O JR | Chief Executive Officer |
Nov 18 '24 |
Buy |
15.00 |
7,500 |
112,500 |
168,655 |
| MOULDER LEON O JR | Chief Executive Officer |
Nov 19 '24 |
Buy |
14.57 |
2,500 |
36,425 |
171,155 |
| MOULDER LEON O JR | Chief Executive Officer |
Sep 18 '24 |
Buy |
17.91 |
10,000 |
179,100 |
1,662,039 |
| MOULDER LEON O JR | Chief Executive Officer |
Sep 20 '24 |
Buy |
18.45 |
5,000 |
92,270 |
1,672,039 |
| MOULDER LEON O JR | Chief Executive Officer |
Sep 19 '24 |
Buy |
17.89 |
5,000 |
89,450 |
1,667,039 |
| Enavate Sciences GP, LLC | 10% Owner |
Sep 16 '24 |
Buy |
17.00 |
882,353 |
15,000,001 |
3,761,359 |
| Lu Hongbo | Director |
Sep 13 '24 |
Buy |
17.00 |
58,823 |
999,991 |
58,823 |
2.51%
자본화:
|
볼륨(24시간):